Zydus-Sunshine JV signs pact with Sri Lanka’s BOI for $20 mn pharma plant

Account subscription benefits alongside Premium Stories, Editorials, Opinions and more. Unlock these with Subscription

Zydus Sunshine Lifesciences, a proposed joint venture between Zydus Lifesciences and Sunshine Healthcare, part of Sunshine Holdings PLC, has signed an agreement with Sri Lanka’s Board of Investment (BOI) to set up a pharmaceutical manufacturing facility in the BOI zone in Horana.

The project entails an investment of $20 million, with the facility spread across nearly four acres. Commercial operations are expected to commence in 2028, subject to project timelines and regulatory approvals, Zydus Lifesciences said on October 15.

The two companies had announced the formation of the joint venture in June.

In the first phase, the facility will manufacture oral solid dosage forms for the Sri Lankan market. The investment is expected to strengthen Zydus’ international presence while bolstering local pharmaceutical manufacturing capacity.

Local production is expected to enhance the resilience of Sri Lanka’s medicine supply chain and improve the availability of essential medicines, the company said.

business (general) / pharmaceutical / medicine / foreign investment / Sri Lanka / international (foreign) trade / India-Sri Lanka

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.